MSPG

Pricing Availability   Qty
Cat.No. 0854 - MSPG | C9H11NO5S | CAS No. 169209-64-7
Description: Group III and group II mGlu antagonist
Chemical Name: (RS)-α-Methyl-4-sulfonophenylglycine
Datasheet
Citations (1)
Reviews
Literature (10)

Biological Activity

Relatively non-selective antagonist of presynaptic mGlu receptors in neonatal rat spinal cord and adult rat cerebrocortical mGlu receptors.

Technical Data

M. Wt 245.25
Formula C9H11NO5S
Storage Store at RT
CAS Number 169209-64-7
PubChem ID 3964410
InChI Key MVDSFPIEJILRME-UHFFFAOYSA-N
Smiles NC(C)(C(O)=O)C1=CC=C(S(=O)(O)=O)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solubility Soluble to 100 mM in 1eq. NaOH

References

References are publications that support the biological activity of the product.

Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71 PMID: 8864696

Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851 PMID: 8532166

Thomas et al (1995) Antagonism of L-AP4- and (1S,3S)-ACPD-induced depression of dorsal root-evoked monosynaptic excitation of neonatal rat motoneurones by the novel antagonists MSPG and MPPG. Br.J.Pharmacol. 114 9P


If you know of a relevant reference for MSPG, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group II Receptor Antagonists

Keywords: MSPG, MSPG supplier, Group, III, group, II, mGlur, antagonists, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGluR4, mGluR6, mGluR7, mGluR8, Glutamate, Metabotropic, mGlu2, mGlu3, mGluR2, mGluR3, (Metabotropic), 0854, Tocris Bioscience

1 Citation for MSPG

Citations are publications that use Tocris products. Selected citations for MSPG include:

McMullan et al (2012) Metabotropic glutamate receptors inhibit microglial glutamate release. ASN Neuro 4 PMID: 22770428


Do you know of a great paper that uses MSPG from Tocris? Please let us know.

Reviews for MSPG

There are currently no reviews for this product. Be the first to review MSPG and earn rewards!

Have you used MSPG?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Pain

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Metabotropic Glutamate Receptors

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.